Filing Analysis
Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. The meeting resulted in the election of three Class II directors and the ratification of Ernst & Young LLP as the independent auditor for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting held virtually on June 26, 2026.
- Elected Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D. as Class II directors to serve until the 2029 Annual Meeting.
- Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
- Total shares outstanding/entitled to vote as of April 27, 2026: 32,723,877 Class A common stock.
Contineum Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended September 30, 2024, and provided a general corporate update via press release.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ending September 30, 2024.
- The company issued a corporate update alongside the earnings release.
- Report date: November 6, 2024.
This is an 8-K/A (Amendment No. 1) filed to correct a broken hyperlink in the original August 13, 2024 filing. The amendment serves to ensure investors can access Exhibit 99.1 containing Q2 2024 financial results and corporate updates.
🚩 Red Flags
- None identified in this specific amendment; it is a technical correction.
📋 Key Facts
- Filed on August 14, 2024, as an amendment to the original 8-K filed on August 13, 2024.
- Purpose of filing is solely to correct a hyperlink to Exhibit 99.1 in Item 9.01 of the original report.
- The original filing contained Q2 2024 financial results and a corporate update (Item 2.02).
- Company updated its corporate presentation on its website (Item 7.01).
Contineum Therapeutics, Inc. issued an 8-K to announce its financial results for the quarter ended June 30, 2024, and provided a corporate update via press release. The company also updated its corporate presentation on its website.
📋 Key Facts
- Reported financial results for the quarter ended June 30, 2024.
- Issued a corporate update alongside the earnings release.
- Updated the corporate presentation available on the company's website.
- The filing is an emerging growth company disclosure.
Contineum Therapeutics, Inc. announced the appointment of Sarah Boyce to its Board of Directors and her designation as Chair of the Nominating and Corporate Governance Committee, effective June 24, 2024.
📋 Key Facts
- Sarah Boyce appointed as a Class I director, effective June 24, 2024.
- Ms. Boyce will serve as Chair of the Nominating and Corporate Governance Committee, replacing Lori Lyons-Williams.
- Compensation includes an initial grant of an option to purchase 29,500 shares of Class A common stock under the existing Non-Employee Director Compensation Program.
- Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc. (RNA) and previously held leadership roles at Akcea Therapeutics, Ionis Pharmaceuticals, and Novartis.
Contineum Therapeutics has adopted an Executive Severance Plan to provide benefits to named executive officers and key employees. The plan includes tiered severance packages triggered by involuntary termination or changes in control.
🚩 Red Flags
- Establishment of severance plans can sometimes precede restructuring or leadership changes, though not explicitly stated here.
📋 Key Facts
- Board adopted the Executive Severance Plan on May 24, 2024.
- CEO Carmine Stengone is designated as a Tier 1 Participant (highest tier).
- CSO Daniel Lorrain and CFO Peter Slover are designated as Tier 2 Participants.
- Tier 1/2 participants receive 12 months of base salary + pro-rated bonus for non-change-in-control terminations.
- Change in control benefits for Tier 1 include 150% of annual base salary and target bonus, plus full vesting of equity awards.
Contineum Therapeutics, Inc. announced the appointment of Troy Ignelzi to its Board of Directors and as Chair of the Audit Committee, effective May 20, 2024. This appointment results in Evert Schimmelpennink stepping down from the Audit Committee.
📋 Key Facts
- Troy Ignelzi appointed to the Board of Directors as a Class I director, term expiring at the 2025 annual meeting.
- Mr. Ignelzi appointed as Chair of the Board’s Audit Committee; designated as an SEC audit committee financial expert.
- Evert Schimmelpennink stepped down from the Audit Committee following the appointment.
- Compensation includes an initial grant of 23,150 options to purchase Class A common stock under the existing Non-Employee Director Compensation Program.
- Mr. Ignelzi previously served as CFO at Karuna Therapeutics and Rapport Therapeutics.
Contineum Therapeutics, Inc. issued an 8-K to furnish its quarterly financial results for the period ended March 31, 2024, alongside a corporate update via press release.
📋 Key Facts
- Report date: May 16, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes financial results and a corporate update in Exhibit 99.1
- Company is an emerging growth company
Contineum Therapeutics, Inc. filed an 8-K to report the adoption of amended and restated articles of incorporation and bylaws in connection with its initial public offering (IPO). The changes include restructuring share classes and establishing governance protocols for a public company.
🚩 Red Flags
- Governance changes (eliminating written consent/special meetings) reduce shareholder control, which is common in IPOs but a structural red flag for minority investors.
📋 Key Facts
- The filing is in direct connection with the closing of the Company's IPO.
- Amended Certificate of Incorporation authorizes 220,000,000 shares (200M Class A; 20M Class B) and 10,000,000 undesignated preferred shares.
- Established a classified board of directors with three classes and staggered three-year terms.
- Implemented high voting thresholds for director removal (66.2/3% vote required).
- Restricted stockholder rights by eliminating the ability to take action by written consent or call special meetings.
- Designated Delaware Court of Chancery as the exclusive forum for derivative actions and federal district courts for Securities Act claims.